These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 31231980)

  • 1. A good start of immunotherapy in esophageal cancer.
    Zhao Q; Yu J; Meng X
    Cancer Med; 2019 Aug; 8(10):4519-4526. PubMed ID: 31231980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies.
    Alsina M; Moehler M; Lorenzen S
    Oncol Res Treat; 2018; 41(5):266-271. PubMed ID: 29705786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for esophageal cancer: a 2019 update.
    Schizas D; Charalampakis N; Kole C; Mylonas KS; Katsaros I; Zhao M; Ajani JA; Psyrri A; Karamouzis MV; Liakakos T
    Immunotherapy; 2020 Feb; 12(3):203-218. PubMed ID: 32208794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging immunotherapy for the treatment of esophageal cancer.
    Jackie Oh S; Han S; Lee W; Lockhart AC
    Expert Opin Investig Drugs; 2016 Jun; 25(6):667-77. PubMed ID: 26950826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Immunotherapy in Advanced Gastroesophageal Cancer.
    Terrero G; Lockhart AC
    Curr Oncol Rep; 2020 Aug; 22(11):112. PubMed ID: 32803457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review).
    Lampis A; Ratti M; Ghidini M; Mirchev MB; Okuducu AF; Valeri N; Hahne JC
    Int J Mol Med; 2021 Jun; 47(6):. PubMed ID: 33846775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?
    Vivaldi C; Catanese S; Massa V; Pecora I; Salani F; Santi S; Lencioni M; Vasile E; Falcone A; Fornaro L
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy for esophageal carcinoma].
    Yamana H
    Nihon Geka Gakkai Zasshi; 2002 Apr; 103(4):376-80. PubMed ID: 11993228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising immunotherapies for esophageal cancer.
    Tanaka T; Nakamura J; Noshiro H
    Expert Opin Biol Ther; 2017 Jun; 17(6):723-733. PubMed ID: 28366014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer.
    Park R; Williamson S; Kasi A; Saeed A
    Anticancer Res; 2018 Oct; 38(10):5569-5580. PubMed ID: 30275174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in pancreatic cancer: New hope or mission impossible?
    Jiang J; Zhou H; Ni C; Hu X; Mou Y; Huang D; Yang L
    Cancer Lett; 2019 Mar; 445():57-64. PubMed ID: 30641107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches in cancer immunotherapy.
    Subramaniam DS; Liu SV; Giaccone G
    Discov Med; 2016 Apr; 21(116):267-74. PubMed ID: 27232512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer.
    Vrána D; Matzenauer M; Neoral Č; Aujeský R; Vrba R; Melichar B; Rušarová N; Bartoušková M; Jankowski J
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for the Treatment of Urothelial Carcinoma.
    Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
    J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current status and prognosis of immune checkpoint inhibitors for esophageal cancer].
    Gao HJ; Shang XB; Yu ZT
    Zhonghua Wai Ke Za Zhi; 2019 Oct; 57(10):77-82. PubMed ID: 31510736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer.
    Ogasawara M; Miyashita M; Yamagishi Y; Ota S
    Ther Apher Dial; 2020 Oct; 24(5):482-491. PubMed ID: 32524770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for esophageal squamous cell carcinoma: a review.
    Mimura K; Yamada L; Ujiie D; Hayase S; Tada T; Hanayama H; Thar Min AK; Shibata M; Momma T; Saze Z; Ohki S; Kono K
    Fukushima J Med Sci; 2018 Aug; 64(2):46-53. PubMed ID: 30058598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Peptide vaccine therapy with TLR-9 agonist for patients with esophageal squamous cell carcinoma].
    Katsuda M; Iwahashi M; Matsuda K; Miyazawa M; Nakamori M; Nakamura M; Naka T; Ojima T; Iida T; Yamaue H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1942-4. PubMed ID: 22202246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.